News - Generics
Pfizer: The Naked Lunch
15 November 2012
Pfizer (PFE), the world's largest pharmaceutical company, has been hit hard by generics. The company has lost patent protection of six of its top brands in the last 12 months. However, its share price has been defying gravity and even trending upward ...
Click on the link to read the full article at Seeking Alpha (This link will open in a new window)Joe and Teresa Graedon: Performance of slow-release generics is questioned
15 November 2012
There was a time when most prescriptions filled in America were for branded drugs. Valium, Prozac and Lipitor were household names. Now, the vast majority of prescriptions are filled with generic equivalents. Diazepam, fluoxetine and atorvastatin are ...
Click on the link to read the full article at Long Beach Press-Telegram (This link will open in a new window)Canada prepares for drug patent concessions to clinch free-trade deal with EU
14 November 2012
"The things that are really difficult are being saved till the end," said John Weekes, a trade consultant who was the chief negotiator for NAFTA and who is now advising the generic drug industry. "The presence of the ministers will create a different ...
Click on the link to read the full article at TheTyee.ca (blog) (This link will open in a new window)Canada works on EU drug deal
14 November 2012
Government and industry sources say Fast is willing to give the EU somewhat stiffer patent protection for brand-name pharmaceuticals, despite intense pressure from the generic drug industry in Canada, health care advocates as well as several provincial ...
Click on the link to read the full article at StarPhoenix (This link will open in a new window)2 Generics of Pfizer's Revatio OK'd
13 November 2012
Pharmaceutical companies Mylan (Nasdaq: MYL ) and Watson Pharmaceuticals (NYSE: WPI ) have announced that they have received FDA approval for generic versions of Pfizer's (NYSE: PFE ) Revatio, a drug used to combat pulmonary arterial ...
Click on the link to read the full article at Motley Fool (This link will open in a new window)AMA Wants To Stop Pharma Pay-To-Delay Tactic On Generics
13 November 2012
The American Medical Association is urging Congress and federal regulators to end the drug industry practice of "pay for delay" which allows brand name pharmaceutical companies to pay generic drug makers to keep cheaper prescriptions off the market.
Click on the link to read the full article at Forbes (This link will open in a new window)Generic OxyContin would be 'tragedy,' Ont. health minister says
13 November 2012
With the powerful painkiller's patent set to expire in just over a week, Ontario's health minister says it will be a ?tragedy? if drug companies are given permission to sell generic versions of OxyContin in Canada. Deb Matthews, along with other ...
Click on the link to read the full article at CTV News (This link will open in a new window)Now Available: Special Report Analyzes the Oncoming Wave of Generic Drugs
13 November 2012
The report also features case studies from leading employers on how they achieved significant savings and improved generic dispensing rates through innovative programs aimed at promoting generics, plus exclusive data from AIS's Quarterly Pharmacy ...
Click on the link to read the full article at Equities.com (This link will open in a new window)2 Risks Facing Merck Today
12 November 2012
Drug sales fall off a cliff after generic drugs come on the market. That's just a fact of life for drug developers. But at least when generics enter the market after a patent expires, investors can see it coming and adjust their valuations accordingly ...
Click on the link to read the full article at Motley Fool (This link will open in a new window)Top U.S. Generic Blockbusters
12 November 2012
The industry has talked nonstop for a couple of years about the patent loss of blockbuster drugs and the impact, earnings losses, job cuts, R&D retrenchment, job losses, CEO job losses. In fact, this year has been the worst, literally. Industry ...
Click on the link to read the full article at FiercePharma (This link will open in a new window)
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
